WO1999015189A1 - Metal compounds, mixed or sulphated, as phosphate binders - Google Patents
Metal compounds, mixed or sulphated, as phosphate binders Download PDFInfo
- Publication number
- WO1999015189A1 WO1999015189A1 PCT/GB1998/002834 GB9802834W WO9915189A1 WO 1999015189 A1 WO1999015189 A1 WO 1999015189A1 GB 9802834 W GB9802834 W GB 9802834W WO 9915189 A1 WO9915189 A1 WO 9915189A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phosphate
- sulphate
- calcium
- compounds
- treated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F11/00—Compounds of calcium, strontium, or barium
- C01F11/18—Carbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F5/00—Compounds of magnesium
- C01F5/24—Magnesium carbonates
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G49/00—Compounds of iron
- C01G49/009—Compounds containing, besides iron, two or more other elements, with the exception of oxygen or hydrogen
Definitions
- This invention relates to metal compounds, especially metal compounds free from aluminium, for pharmaceutical application, especially as phosphate binders.
- WO-A-94/09798 discloses mixtures or complexes containing calcium and sulphate for use in a wide variety of pharmaceutical applications.
- the mixtures or complexes are inorganic compositions derivable from peat, in the form of aqueous solutions or synthetic syngenite (CaS0 4 .K 2 SO 4 .H 2 O) materials. There is no reference to their phosphate binding capacity.
- Such current phosphate binders effective at pH3 would not necessarily bind as effectively at higher pH, eg >7, which obtain in the lower tract, eg duodenum and below, and where at least some of the binding of phosphate may take place.
- particularly alkaline binders could buffer the stomach pH up to a high level at which they would not have a phosphate binding capacity.
- certain mixed metal compounds which are free from aluminium, may bind at least 30% by weight of the total weight of phosphate present over a pH range of from 2-8.
- the invention provides a mixed metal compound for pharmaceutical use which is free from aluminium and which has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8.
- the invention provides the use, in the preparation of a medicament for treating hyperphosphataemia, of a mixed metal compound free from aluminium and having a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8.
- Such mixed metal compounds may contain iron (III) and at least one of magnesium, calcium, lanthanum and cerium.
- the mixed metai compounds contain at least one of hydroxyl and carbonate anions and optionally additionally, at least one of sulphate, chloride and oxide.
- preferred mixed metal hydroxy carbonates containing each of magnesium and iron are of a hydrotalcite structure.
- the ratio of Ca 2+ : Fe 3+ is at least 2:1., still more preferably at least 3:1.
- An alternative preferred compound contains Ca 2+ , Mg 2+ and Fe 3+ , more preferably in a ratio of 3:3:2.
- the invention provides metal sulphate material for pharmaceutical use, which metal sulphate material is selected from at least one of calcium, lanthanum and cerium sulphate compounds treated with an alkali solution, preferably an aqueous solution of an alkaline hydroxide, more preferably sodium hydroxide, which said material comprises a solid material, especially a solid material or a suspension of a solid material in a liquid especially aqueous, medium.
- a metal sulphate material selected from at least one of calcium, lanthanum and cerium sulphate compounds treated with an alkali solution.
- a method of preparing a metal sulphate material comprises treating a metal sulphate selected from at least one of calcium, lanthanum and cerium sulphate with an alkali solution.
- Fig. 1 shows the effect of pH and ageing on percentage phosphate binding of mixed metal compounds.
- Fig.1 o Mg:Fe 3:1 prep 2 unaged
- Fig.2 shows the effect of pH and drying on percentage phosphate binding of mixed metal compounds.
- Fig. 2 shows the effect of pH and drying on percentage phosphate binding of mixed metal compounds.
- Fig. 3 shows the effect of increasing weight of compound on percentage phosphate bound at pH3.
- Fig. 4 shows the effect of increasing we sight of compound on percentage phosphate bound at pH7.
- Fig. 5 shows the time course of phosphate binding in food.
- Fig. 6 shows the effect of phosphate binding by the calcium ferric iron preparations over the pH range 3-8.
- Fig. 7 shows the effect of phosphate binding by the magnesium ferric iron and calcium magnesium ferric iron preparations over the pH range 3-8.
- Fig. 7 shows the effect of phosphate binding by the magnesium ferric iron and calcium magnesium ferric iron preparations over the pH range 3-8.
- Fig. 8 shows the effect of phosphate binding by aluminium hydroxide, magnesium hydroxide and calcium carbonate over the pH range 3-8.
- Fig. 8 shows the effect of phosphate binding by aluminium hydroxide, magnesium hydroxide and calcium carbonate over the pH range 3-8.
- FIG. 9 shows the individual and mean ( ⁇ 1 SEM) urinary phosphate excretion for control rats and those treated with phosphate binding compounds.
- individual values of urinary phosphate excretion ( ⁇ mol/24hours) were plotted for controls ( ⁇ ) and animals treated with AI(OH) 3 ( ⁇ ), CaC0 3 (D), CTFeCa (•), Mg(OH) 2 (O), CT100 ( ⁇ ) and CTFeMg (0).
- Mean ( ⁇ SEM) for each group are presented by points with error bars. *p ⁇ 0.05 compared to AI(OH) 3 treated animal groups; and Fig.
- FIG. 10 shows the mean ( ⁇ 1SEM) soluble faecal phosphate (g "1 dry weight) as a percentage of total (soluble and unsoluble) faecal phosphate (g "1 dry weight) for control rats and those treated with phosphate binding compounds.
- ⁇ 1SEM soluble faecal phosphate
- CT100 is a hydrotalcite of the formula Ai 2 Mg 6 OH 16 .CO 3 .4H 2 0, commercially available from Crosfield Limited (UK)and CT2000 is the compound CT100 in the form of an undried slurry.
- the phosphate binding capacity was measured by mixing 3.2mmol of the compound with 25ml of 20mmol I "1 phosphate buffer for 30min at 25°C.
- CT2000 which compounds were dry powders, the compounds were merely weighed and dosed.
- CT2000 the slurry was dosed in an amount such as to give an equivalent of 1g of a powder dried to constant weight at 40°C.
- Sodium phosphate and sodium hydrogen phosphate were mixed to provide respective phosphate solutions at pH3, 7 and 8 (HCI being added to provide pH3).
- n refers to the number of observations and the values as the % of phosphate precipitated out of solution, calculated as follows:
- each of the hyd rota I cite-like materials had a considerably higher phosphate binding capacity over a wider pH range.
- Dosage relationship curves for the CT compounds and AI(OH) 3 in pH3, 5 and 7 phosphate buffer showed that the CT compounds bound at least twice as much phosphate as an equivalent weight of AI(OH) 3 .
- AI(OH) 3 released as much as 20,000-41 , OOO ⁇ g I -1 of Al 3+ . Moreover, although the CT compounds released a considerably lower amount (17-66 ⁇ g I "1 ), this would still be likely to provide adverse effects in long time-dosage regimes.
- Altacite a hydrotalcite of the same formula as CT100, commercially available from Roussell, in the form of an aqueous slurry
- Method 2 As method 1 but using 20 mmol 1 '1 phosphate buffer.
- Method 3 Milk (250 ml), cornflakes (50 g), bread (2 slices) and marmite (5 g) were mixed in a stomacher for 30 minutes containing 0.01 M HCI (so as to simulate the conditions in the stomach). A 20 ml aliquot of food was removed and centrifuged. Phosphate was measured in the supernatant. Two grams of the phosphate binder compound was added to the bulk food slurry and mixed for a further 30 minutes. An aliquot of food was taken and the phosphate measured in the supernatant following centrifugation. Further aliquots were taken after a further 30 and 90 minutes mixing.
- Phosphate binding compounds were prepared in the form of a wet slurry. Unaged samples were obtained by filtering and washing the wet slurry to form a wet cake which was tested in this form, while aged samples were obtained by heating the wet slurry to 80°C for two hours prior to filtering of the cake, which was then tested. The percentage phosphate binding of the compounds when used aged or unaged across the pH range 3-7 was investigated in this manner.
- Method 1 was used for measuring phosphate binding capacity. The results are shown in Fig. 1.
- the Ca:Fe 3:1 compound (3) bound almost 100% of the phosphate independently of pH. There was no difference between the aged and unaged compound.
- Method 1 was used for measuring phosphate binding capacity. The results are shown in Fig. 2.
- Unaged compounds were compared in their wet (cake) form or following drying to constant weight. One gram weight of each compound was used for comparison (hydration of the wet (cake) compound was accounted for e.g. if the hydrotalcite was 20% dry weight (calculated on a constant dry weight at 40°C), 5 grams were used).
- Method 2 was used for measuring phosphate binding capacity. The results are shown in Fig. 3. At pH 3, Mg(OH) 2 , compound (7), was the best phosphate binder. Other studies have however showed this binding is pH dependent, binding almost no phosphate at pH 8. It would therefore have limited use in vivo.
- AI(OH) 3 the phosphate binder often used to control serum phosphate levels was relatively ineffective at the range of weights tested.
- the Mg:Fe 3:1 compound (2) was the best phosphate binder over the range of weights studied.
- the CT100 (5) bound at least twice as much phosphate than the Altacite (6) at any weight studied.
- the Mg:Fe and Ca:Fe compounds (1 )-(4) were efficient phosphate binders across a range of pH's likely to be found in the gastrointestinal tract.
- the metals in the solutions/suspensions described in Table 1 were precipitated at the same time by the addition of sodium hydroxide.
- a preparation was also made by precipitating the calcium and iron separately with sodium hydroxide, the precipitates were then mixed.
- Fe 2 (S0 4 ) 3 (1 mole) and NaOH (6 moles) were mixed in 4 litres de- ionised H 2 0.
- CaS0 4 (6 moles), NaOH (12 moles) and Na 2 CO 3 (5 moles) were mixed. These two suspensions were then fed with into the flask with an overflow at ⁇ 2 litres and constantly mixed.
- Preparations were washed and dried to constant dry weight in an oven at ⁇ 40°C. One gram was titrated against 1 M HCI until a constant pH of 1 was attained. The concentrations of M 2+ and M 3+ ions in solution were measured. For iron and calcium a Hitachi 911 autoanalyser with Boehringer Mannheim chemistry was used, while for magnesium a flame photometric atomic absorption spectroscopy was employed.
- Phosphate binding for the compounds prepared above when dosed as a dry powder, was measured in each case at a dosage of 1.0 gram dry weight (determined by drying to constant weight at 40°C). Where a wet cake was dosed, an amount equivalent to a 1g dry weight was added. Phosphate binding of the conventional binders, magnesium hydroxide, aluminium hydroxide and calcium carbonate was also measured, in these cases using 1g of material as supplied.
- Phosphate binding capacity was determined over a pH range 3-8, approximately the range of pH's found in the normal gastrointestinal tract.
- 40 mmol 1 "1 sodium phosphate buffers at pH 5, pH 7 and pH 8 were produced by mixing appropriate volumes of 40 mmol 1 "1 Na 2 HP0 4 and 40 mmol 1 "1 NaH 2 P0 4 solutions.
- a pH 3 phosphate solution was produced by addition of 1 M HCI to a 40 mmol ⁇ 1 NaH 2 P0 4 solution.
- Preparations were suspended in 25 ml 40 mmol 1 "1 phosphate buffer and whirl mixed to ensure homogeneity. This suspension was then gently agitated at room temperature for 30 minutes followed by centrifugation at 3000 rpm for 5 min. Following filtration of the supernatant through 0.22 ⁇ m millipore filters, soluble phosphate was measured using a 911 Hitachi autoanalyser with Boehringer Mannheim chemistry.
- Phosphate bound was calculated as a percentage of that present in the original solution.
- compositions of solutions used to produce the metal co-precipitate preparations are shown in Table 2 below.
- a preparation was made to determine whether precipitation of calcium and ferric iron from their sulphates prior to mixing would produce a phosphate binding material.
- This compound was prepared as in methods M2.
- the predicted ratio of calcium to ferric iron was 3:1 although, the ratio measured following acid hydrolysis was 1.1 :1.
- Preparation 1 had an actual Mg 2+ :Fe 3+ ratio of 2.4:1
- Preparations 2, 3 and 4 had measured Mg 2+ :Fe 3+ ratios of 2.2:1 , 2.2:1 and 2.3:1 respectively.
- Preparation 1 bound at least 60% of the phosphate over the pH range 3-7.
- Preparations 2, 3 and 4 bound at least 40%, 50% and 30% of the phosphate respectively over the pH range 3-8 (Fig. 7, Table 6) ⁇ Phosphate binding by preparation 4 was reproducible (Table 6).
- a shortage of material meant binding experiments on preparations 1 , 2 and 3 were carried out once.
- Preparation 1 bound greater than 60% of the phosphate across the pH range 3-7.
- Preparation 2 reproducibly bound greater than 30% of the phosphate across the pH range 3-8 (Table 7, Fig. 7). This was pH dependent with a mean of 27% less phosphate being bound at pH 8 than pH 3.
- Table 7 Phosphate binding for preparations with the predicted 2:1 Mg 2+ :Fe 3+ ratio
- the compounds aluminium hydroxide, magnesium hydroxide and calcium carbonate were also tested for their ability to bind phosphate.
- the method was as previously described in M4.
- phosphate binding was pH dependent with a mean 2.4 fold increase in binding by AI(OH) 3 at pH 3 compared to pH 8.
- Mg(OH) 2 bound a mean 3.7 times more phosphate at pH 3 than pH 8.
- CaCO 3 bound a mean of 5.9 times more phosphate at pH 3 than pH 8.
- the mixture was centrifuged for 5 min at 3000 rpm and the supernatant discarded.
- the precipitate was washed by mixing with 100ml water for 5 minutes followed by centrifugation for 5 min at 3000 rpm. The supernatant was discarded and the washing procedure repeated a further 3 times.
- the precipitate was heated to constant dry weight at 60°C.
- the phosphate binding capacity of each of the above materials was measured as described above in Example 3, using one gram of each compound in 25 ml phosphate solution 40 mmol 1 ' ⁇ pH 3-8.
- Table 10 Phosphate binding over the pH range 3-8 by alkali treated calcium sulphate, anhydrous and hydrated calcium sulphates and an Fe 2+ :Fe 3+ compound with a predicted 3:1 ratio and an Fe 3+ compound
- mixed metal compounds preferably containing each of a ferric cations and at least one of magnesium, calcium, lanthanum and cerium cation, and at least one of hydroxyl and carbonate anions and optionally at least one of sulphate, chloride and oxide have excellent phosphate binding capacity at a buffer pH relevant to physiological conditions in the gastrointestinal tract.
- they show excellent phosphate binding capacity over a pH range of from 2-8, especially 3-7, and are therefore able to bind phosphate both in the stomach region (upper tract) where the pH would normally be about 3-4, up to 7, possibly depending upon the pH of the binder itself, and also in the lower tract, for example in the duodenum or jejunum, where the pH is likely to be >7.
- a mixed calcium/ferric compound contains less ferric ion than the corresponding compound containing iron alone. This allows a small in vivo dosage of iron for at least the same phosphate binding capacity, thus raising the likely tolerance of a patient to the dosage given.
- the phosphate binding capacity of the mixed magnesium/ferric compound is also remarkably less pH dependent as compared with magnesium hydroxide.
- the magnesium tends to be stabilised, leading to a lower expected release thereof when administered in vivo with expected reduced side effects such as hypermagnesaemia.
- the iron tends to be stabilised, leading to a lower expected release thereof in vivo, with an expected reduction in the free radical formation in vivo often encountered with Fe 3+ ions, so leading to less damage of membrane tissue.
- CTFeCa and CTFeMg were mixed metal hydroaltacites, having a predicted ratio of Mg 2+ or Ca 2+ :Fe 3+ of 3:1 , produced in the laboratory following a standard laboratory procedure for mixed metal hydroxy carbonate preparations as described in Example 3 (M2).
- This metal 2"1" sulphate, 6 moles, and metal 3"1" sulphate, 2 moles, were dissolved in 4 litres de-ionised H 2 O.
- 16 moles NaOH and 5 moles Na 2 C0 3 were dissolved in 4 litres de-ionised H 2 O.
- the phosphate binders were incorporated into the rat food at a concentration of 1% (w/w).
- Each group of rats was fed a single diet ad libitum for seven days and had unlimited access to de-ionised water. Animals were then weighed and transferred to metabowls for 24 hours where they received 18 grams of the control diet and unlimited access to water. Total 24 hour urine and faecal output was collected during this time.
- the rat faeces were unavoidably contaminated with control food from the diet and there was also slight contamination of the urine. Prior to analysis, food was therefore separated from the urine by 5 minutes centrifugation at 1500 rpm. The food pellet was discarded. Contaminating particulate food was removed from the faeces using forceps and the stool sample weighed.
- freeze dried faeces was ground with a mortar and pestle and 200mg hydrolysed by heating to 70°C for 4 hours with 7ml concentrated nitric acid in polypropylene test tubes.
- the faecal digests were diluted to 50ml with de-ionised water in acid washed 125ml Nalgene containers.
- soluble faecal phosphate and metal ion content For measurement of soluble faecal phosphate and metal ion content, a 1.5 gram aliquot of stool was suspended in 15 ml deionised water. Following homogenisation and centrifugation at 3000 rpm for 45 minutes, the supernatant was filtered through glass wool to remove contaminating particulate matter and stored at -20°C.
- Phosphate, iron and calcium were determined in the faecal digest solutions, urine and serum using standard Boehringher Mannheim chemistry on a Hitachi 911 autoanalyser. Magnesium was measured in the faecal digest solutions, urine and serum using flame photometry atomic absorption spectrometry. Urine and serum aluminium were measured using graphite furnace atomic absorption spectrometry.
- mice Following feeding with the modified diets for 7 days, animals were transferred to metabowls for collection of total 24 hour faecal and urine excretion. To ensure that any contamination of faeces and urine by food was similar for the different groups, each animal was given a restricted 18 grams of control diet (Lilico). During this period, control animals gained a mean of 3 grams in weight. Other animal groups showed a mean weight loss of 2 -22 grams. Results
- Reduced phosphate absorption achieved when a dosage of the inorganic compound is ingested with food is manifested by a low urine phosphate content, a high total faecal phosphate content and a low ratio of soluble faecal phosphate content: total faecal phosphate content (Table 11 ).
- phosphate binders were precipitating phosphate in the rat gastrointestinal tract.
- total stool phosphate (bound and soluble) and soluble stool phosphate (unbound) were measured.
- faecal phosphate was expressed as ⁇ mol phosphate g "1 dry weight faeces.
- Total (soluble and insoluble) phosphate g "1 dry weight faeces did not differ significantly between any of the treatment groups. Faeces from animals treated with CTFeCa contained significantly less soluble phosphate than the controls or the animals treated with CaC0 3 (Table 1 1 ).
- Urine and serum aluminium concentrations were measured using graphite furance atomic absorption spectroscopy.
- mean serum aluminium concentrations were not significantly higher that serum aluminium from control animals (Table 12).
- animals treated with CTFeCa and CTFeMg showed the highest mean serum aluminium concentrations, both significantly higher than animals treated with Mg(OH) 2 , AI(OH) 3 , CaCO 3 or controls.
- Urinary magnesium excretion following treatment with the compounds CT100 and CTFeMg was higher although not significantly so compared to the control animals (Table 14). Following Mg(OH) 2 administration, urine magnesium excretion was significantly higher than the control group or animals treated with any other binder.
- iron concentration was at the limit of detection of the method employed (>1 ⁇ mol 1 "1 ).
- magnesium carbonate has been shown to be an efficient binder [O'Donovan et.al., Lancet, (1986), 5JL 880-881] while magnesium hydroxide has been shown to be ineffective or poorly tolerated [Guillot et al., Nephron, (1982), 30, 114-117; Oe et al., Colin. Nephrol, (1987), £8, 180-185]. Care must be taken though to avoid over administration due to the laxative effects of magnesium.
- CT100, CTFeMg and CTFeCa are all high capacity phosphate binders when administered in vivo to rats at low doses. This study indicates they are likely to have limited toxicity although long time course studies are required to evaluate iron, aluminium and magnesium absorption. These compounds may present effective alternatives to the currently prescribed phosphate binders.
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL98339079A PL194211B1 (en) | 1997-09-19 | 1998-09-18 | Compounds of metals, mixed or sulphate-type ones, as agent capable to bond phosphates |
CA2303820A CA2303820C (en) | 1997-09-19 | 1998-09-18 | Metal compounds, mixed or sulphated, as phosphate binders |
EP98944055A EP1015002B1 (en) | 1997-09-19 | 1998-09-18 | Aluminium free mixed metal compounds as phosphate binders |
BR9812223-1A BR9812223A (en) | 1997-09-19 | 1998-09-18 | Mixed metal compound, uses of a mixed metal compound and a metal sulphate material, metal sulphate material, and, process for preparing a metal sulphate material |
NZ503136A NZ503136A (en) | 1997-09-19 | 1998-09-18 | Sulphated metal compounds as phosphate binders |
US09/508,923 US6926912B1 (en) | 1997-09-19 | 1998-09-18 | Metal compounds, mixed or sulphated, as phosphate binders |
KR1020007002892A KR100823565B1 (en) | 1997-09-19 | 1998-09-18 | Metal compounds, mixed or sulphated, as phosphate binders |
JP2000512558A JP4149659B2 (en) | 1997-09-19 | 1998-09-18 | Mixed or sulfate metal salt compounds as phosphate binders |
HU0004527A HU227666B1 (en) | 1997-09-19 | 1998-09-18 | Metal compounds, mixed or sulphated, as phosphate binders |
HU0900652A HU230611B1 (en) | 1997-09-19 | 1998-09-18 | Metal compounds, mixed or sulphated, as phosphate binders |
AU91733/98A AU9173398A (en) | 1997-09-19 | 1998-09-18 | Metal compounds, mixed or sulphated, as phosphate binders |
DE69835217T DE69835217T2 (en) | 1997-09-19 | 1998-09-18 | Aluminum-free mixed metal compositions as phosphate binders |
KR1020077001491A KR100997504B1 (en) | 1997-09-19 | 1998-09-18 | Metal compounds, mixed or sulphated, as phosphate binders |
US10/615,797 US7799351B2 (en) | 1997-09-19 | 2003-07-10 | Metal compounds, mixed or sulphated, as phosphate binders |
CY20061101402T CY1106174T1 (en) | 1997-09-19 | 2006-09-28 | ALUMINUM-FREE MIXED METAL COMPOUNDS AS PHOSPHATE BINDING AGENTS |
US12/828,462 US8568792B2 (en) | 1997-09-19 | 2010-07-01 | Metal compounds, mixed or sulphated, as phosphate binders |
US14/065,162 US9242869B2 (en) | 1997-09-19 | 2013-10-28 | Metal compounds mixed or sulphated, as phosphate binders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9720061.2 | 1997-09-19 | ||
GBGB9720061.2A GB9720061D0 (en) | 1997-09-19 | 1997-09-19 | Metal compounds as phosphate binders |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09508923 A-371-Of-International | 1998-09-18 | ||
US09/508,923 A-371-Of-International US6926912B1 (en) | 1997-09-19 | 1998-09-18 | Metal compounds, mixed or sulphated, as phosphate binders |
US10/615,797 Continuation US7799351B2 (en) | 1997-09-19 | 2003-07-10 | Metal compounds, mixed or sulphated, as phosphate binders |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999015189A1 true WO1999015189A1 (en) | 1999-04-01 |
Family
ID=10819414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/002834 WO1999015189A1 (en) | 1997-09-19 | 1998-09-18 | Metal compounds, mixed or sulphated, as phosphate binders |
Country Status (20)
Country | Link |
---|---|
US (4) | US6926912B1 (en) |
EP (2) | EP1759704B1 (en) |
JP (3) | JP4149659B2 (en) |
KR (2) | KR100997504B1 (en) |
CN (2) | CN1911245B (en) |
AT (2) | ATE332699T1 (en) |
AU (1) | AU9173398A (en) |
BR (1) | BR9812223A (en) |
CA (1) | CA2303820C (en) |
CY (2) | CY1106174T1 (en) |
DE (2) | DE69842028D1 (en) |
DK (2) | DK1015002T3 (en) |
ES (2) | ES2355925T3 (en) |
GB (1) | GB9720061D0 (en) |
HK (1) | HK1098390A1 (en) |
HU (2) | HU230611B1 (en) |
NZ (1) | NZ503136A (en) |
PL (1) | PL194211B1 (en) |
PT (2) | PT1015002E (en) |
WO (1) | WO1999015189A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1046410A2 (en) * | 1999-04-20 | 2000-10-25 | Vitasyn GmbH | Calcium and magnesium containing phosphate binding agent for the treatment of hyperphosphatemia |
WO2004016553A2 (en) * | 2002-08-14 | 2004-02-26 | Altair Nanomaterials Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
WO2006000547A2 (en) * | 2004-06-28 | 2006-01-05 | Vifor (International) Ag | Method for producing an iron sulfate-based phosphate adsorbent |
EP1647524A2 (en) * | 2002-08-14 | 2006-04-19 | Altair Nanomaterials Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
WO2006085079A2 (en) * | 2005-02-10 | 2006-08-17 | Ineos Healthcare Limited | Pharmaceutically active phosphate binders, their manufacture, compositions containing them and their use |
EP1708723A4 (en) * | 2004-07-27 | 2006-12-20 | Shire Pharmaceuticals Inc | Method of treating hyperphosphataemia using lanthanum hydroxycarbonate |
WO2007088343A2 (en) * | 2006-01-31 | 2007-08-09 | Ineos Healthcare Limited | Granular material comprising water- insoluble inorganic phosphate binders |
EP1932807A1 (en) * | 2006-12-14 | 2008-06-18 | Novartis AG | Inorganic compounds |
US7465465B2 (en) * | 2003-08-26 | 2008-12-16 | Shire Biochem Inc. | Pharmaceutical formulation comprising lanthanum compounds |
WO2009016349A1 (en) * | 2007-07-27 | 2009-02-05 | Ineos Healthcare Limited | Mixed metal compounds used as antacids |
CN101378730A (en) * | 2006-01-31 | 2009-03-04 | 英力士保健有限公司 | Granular material comprising water-insoluble inorganic phosphate binders |
WO2009050468A1 (en) | 2007-10-16 | 2009-04-23 | Ineos Healthcare Limited | Mixed metal compounds for treatment of hyperphos phataemia |
US7799351B2 (en) | 1997-09-19 | 2010-09-21 | Ineos Healthcare Limited | Metal compounds, mixed or sulphated, as phosphate binders |
WO2011015859A1 (en) | 2009-08-03 | 2011-02-10 | Ineos Healthcare Limited | Method |
WO2011048097A1 (en) * | 2009-10-21 | 2011-04-28 | Freie Universität Berlin | Bismuth-containing composition for reducing the phosphate concentration in fluids |
WO2011095812A2 (en) | 2010-02-04 | 2011-08-11 | Ineos Healthcare Limited | Composition |
US8252310B2 (en) | 2006-12-14 | 2012-08-28 | Novartis Ag | Manufacture process |
US8715603B2 (en) | 2002-05-24 | 2014-05-06 | Spectrum Pharmaceuticals, Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
US8961917B2 (en) | 2010-05-12 | 2015-02-24 | Spectrum Pharmaceuticals, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
US9339481B2 (en) | 2009-04-10 | 2016-05-17 | Cypress Pharmaceuticals, Inc. | Phosphate-binding magnesium salts and uses thereof |
US9394318B2 (en) | 2012-11-30 | 2016-07-19 | Cypress Pharmaceuticals, Inc. | Crystal polymorph of magnesium glycinate dihydrate and process for its preparation |
AU2016213745B2 (en) * | 2006-01-31 | 2019-03-14 | Cytochroma Development Inc. | Granular Material Comprising Water-Insoluble Inorganic Phosphate Binders |
WO2020084349A1 (en) | 2018-10-25 | 2020-04-30 | Opko Ireland Global Holdings, Ltd | Methods of treatment with mixed metal compounds |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100526219C (en) * | 2002-08-14 | 2009-08-12 | 爱尔达纳米公司 | Rare earth metal compounds, methods of making, and methods of using the same |
EP1830832A1 (en) * | 2004-12-30 | 2007-09-12 | Genzyme Corporation | Zinc-containing treatments for hyperphosphatemia |
JPWO2006132321A1 (en) * | 2005-06-09 | 2009-01-08 | ジェイファーマ株式会社 | Phosphorus disorder preventive and improving therapeutic agent and method for producing the same |
WO2007027566A2 (en) | 2005-09-02 | 2007-03-08 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
WO2007056405A2 (en) * | 2005-11-08 | 2007-05-18 | Genzyme Corporation | Magnesium-containing polymers for the treatment of hyperphosphatemia |
BRPI0621776A2 (en) * | 2006-06-29 | 2011-12-20 | Pharma Co Ltd J | therapeutic medicinal preventive agent for decreasing phosphorus, oral agent for adsorbing phosphate ions contained in food, beverages, and process for producing it |
JP2009542653A (en) * | 2006-07-05 | 2009-12-03 | ジェンザイム コーポレーション | Iron (II) containing therapeutic agent for hyperphosphatemia |
JP4513819B2 (en) | 2007-03-19 | 2010-07-28 | 株式会社日立製作所 | Video conversion device, video display device, and video conversion method |
AR076070A1 (en) * | 2009-03-02 | 2011-05-18 | Vifor Int Ag | PHOSPHATE ABSORBENT FOR THE TREATMENT OF HYPERPHOSPHATEMIA |
CA2756942C (en) * | 2009-04-10 | 2019-01-08 | Cypress Pharmaceuticals, Inc. | Phosphate-binding magnesium salts and uses thereof |
JP5336932B2 (en) * | 2009-05-29 | 2013-11-06 | 株式会社東芝 | Water purification material, water purification method, phosphate fertilizer precursor and method for producing phosphate fertilizer precursor |
DE102011112898A1 (en) * | 2011-09-08 | 2013-03-14 | Charité - Universitätsmedizin Berlin | Nanoparticulate phosphate adsorbent based on maghemite or maghemite / magnetite, its preparation and uses |
CN112816575A (en) * | 2020-12-29 | 2021-05-18 | 平光制药股份有限公司 | Analysis method for phosphate binding force of sevelamer carbonate |
CN115024495B (en) * | 2022-06-27 | 2024-03-22 | 北京金康普食品科技有限公司 | Nutritional composition for improving calcium and phosphorus metabolism of nephrosis patient and application thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU414849A1 (en) * | 1971-05-21 | 1977-09-05 | Харьковский домостроительный комбинат | Concrete mix |
DE3402878A1 (en) * | 1984-01-27 | 1985-08-01 | Algina AG, Zug | MEDICINAL PRODUCTS AND THE USE OF HEAVY-SOLUBLE CALCIUM AND / OR MAGNESIUM COMPOUNDS AS MEDICINAL PRODUCTS |
JPS6136222A (en) * | 1984-07-26 | 1986-02-20 | Chugai Pharmaceut Co Ltd | Remedy for hyperphosphatemia |
JPS62145024A (en) * | 1985-12-19 | 1987-06-29 | Asahi Chem Ind Co Ltd | Immobilizing agent for phosphate ion |
GB2254556A (en) * | 1991-04-11 | 1992-10-14 | Fisons Plc | Linolenic acid formulations |
JPH05155776A (en) * | 1991-12-02 | 1993-06-22 | Otsuka Pharmaceut Factory Inc | Therapeutic agent for hyperphosphatemia |
WO1996030029A1 (en) * | 1995-03-25 | 1996-10-03 | Johnson Matthey Public Limited Company | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
US5571336A (en) * | 1995-09-29 | 1996-11-05 | Wurzburger; Stephen R. | Base solution for cleaning aluminum |
WO1997022266A1 (en) * | 1995-12-19 | 1997-06-26 | Vifor (International) Ag | Adsorbent for phosphate from an aqueous medium, production and use of said adsorbent |
US5654011A (en) * | 1996-07-30 | 1997-08-05 | Energetics, Inc. | Dietary supplements |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2222924A (en) * | 1936-12-10 | 1940-11-26 | Degussa | Preparation of cerium sulphate |
US2812344A (en) * | 1956-02-13 | 1957-11-05 | Ortho Pharma Corp | Ferrous calcium citrate complex |
FR1214473A (en) * | 1959-01-07 | 1960-04-08 | Process for preparing a catalyst based on cerium hydroxide | |
BE590192A (en) | 1959-04-27 | |||
US3395211A (en) * | 1965-12-10 | 1968-07-30 | Carter Wallace | Tableting process |
US3539306A (en) * | 1966-07-25 | 1970-11-10 | Kyowa Chem Ind Co Ltd | Process for the preparation of hydrotalcite |
US3796792A (en) * | 1969-12-12 | 1974-03-12 | Kyowa Chem Ind Co Ltd | Composite metal hydroxides |
BE792032A (en) | 1971-12-23 | 1973-03-16 | Baxter Laboratories Inc | MASS TRANSFER DEVICE WITH A SEMI-PERMEABLE MEMBRAME ARRANGED IN A SPIRAL AND PRESENT A LOW VOLUME OF FLUID |
NL174720C (en) | 1973-12-13 | 1984-08-01 | Philips Nv | IMAGE DISPLAY CELL AND METHOD FOR THE MANUFACTURE OF A LIQUID CRYSTALLINE P-N-BUTYL-P'-ALKOXYAZOBENZENE. |
JPS5417518Y2 (en) | 1975-06-05 | 1979-07-05 | ||
PL110490B1 (en) | 1976-05-19 | 1980-07-31 | Politechnika Poznanska | Agent for preparing hydrophobic solutions extracting ions of non ferrous metals from aqueous solutions also a method of producing an agent for preparing hydrophobic solutions extracting ions of non ferrous metals |
DE2642984C3 (en) | 1976-09-24 | 1980-01-24 | Maschinenfabrik Karl Brieden & Co, 4630 Bochum | Discharge line with discharge at the front |
FR2435442A1 (en) | 1978-09-07 | 1980-04-04 | Om Lab Sa | SYNTHETIC MAGNESIUM AND ALUMINUM SILICATE, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME |
US4192900A (en) | 1978-10-12 | 1980-03-11 | Merck & Co., Inc. | Texturized starch products |
DE2845326C2 (en) * | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Use of a specific microdisperse, amorphous, porous silica for the production of digoxin-containing tablets with a strongly accelerated release of active ingredient |
DE3039997A1 (en) * | 1980-10-23 | 1982-06-03 | Bayer Ag, 5090 Leverkusen | PHOSPHONOHYDROXYACETONITRILE, A METHOD FOR THE PRODUCTION THEREOF AND ITS USE AS AN INTERMEDIATE PRODUCT FOR THE PRODUCTION OF MEDICINAL PRODUCTS |
US4351814A (en) * | 1980-12-18 | 1982-09-28 | Kyowa Chemical Industry Co., Ltd. | Hydrotalcites having a hexagonal needle-like crystal structure and process for production thereof |
JPS57156419A (en) * | 1981-03-24 | 1982-09-27 | Kyowa Chem Ind Co Ltd | Remedy for sideropenia |
US4514389A (en) * | 1981-05-06 | 1985-04-30 | Kyowa Chemical Industry Co. Ltd. | Gastric antacid and method for controlling pH of gastric juice |
CA1198674A (en) | 1981-11-23 | 1985-12-31 | Rorer International (Holdings) Inc. | Antacid compositions |
US4458026A (en) * | 1982-06-02 | 1984-07-03 | Union Carbide Corporation | Catalysts for aldol condensations |
US4582705A (en) * | 1982-07-12 | 1986-04-15 | Leonard Primes | Composition for detoxification |
DE3228231A1 (en) * | 1982-07-28 | 1984-02-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München | MEDICINAL PRODUCTS, CALCIUM MIXED SALTS OF POLYMERS, ANIONIC CARBONIC ACIDS AND / OR SULFURIC ACID ESTERS, PROCESS FOR THEIR PRODUCTION AND THEIR USE |
JPS606619A (en) | 1983-06-27 | 1985-01-14 | Kyowa Chem Ind Co Ltd | Remedy for hypoferremia and its preparation |
GB8317595D0 (en) | 1983-06-29 | 1983-08-03 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions |
US4609543A (en) * | 1983-11-14 | 1986-09-02 | Nabisco Brands, Inc. | Soft homogeneous antacid tablet |
JPS60131604A (en) * | 1983-12-20 | 1985-07-13 | Victor Co Of Japan Ltd | Magnetic recording and reproducing element |
DE3346943A1 (en) | 1983-12-24 | 1985-07-04 | Bayer Ag, 5090 Leverkusen | Preparation of hydrotalcite with improved properties |
FR2559755A1 (en) * | 1984-02-20 | 1985-08-23 | Rhone Poulenc Spec Chim | CERIC OXIDE WITH NEW MORPHOLOGICAL CHARACTERISTICS AND METHOD OF OBTAINING THE SAME |
US4566986A (en) * | 1984-08-31 | 1986-01-28 | Waldmann John J | Flocculating agents and processes for making them |
DE3520108A1 (en) * | 1985-06-05 | 1986-12-11 | Varta Batterie Ag, 3000 Hannover | POSITIVE COLLECTOR ELECTRODE FOR ACCUMULATORS WITH ALKALINE ELECTROLYTE |
US6749864B2 (en) | 1986-02-13 | 2004-06-15 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
US4871392A (en) | 1986-05-23 | 1989-10-03 | American Cyanamid Company | Aqueous suspension concentrate compositions of pendimethalin |
US4801454A (en) | 1986-07-17 | 1989-01-31 | The Proctor & Gamble Company | Processes for making colored pharmaceutical compositions |
ES2024666B3 (en) * | 1987-06-29 | 1992-03-01 | Rhone-Poulenc Chimie | PROCEDURE FOR OBTAINING A CERIC OXIDE. |
US4994283A (en) * | 1987-07-02 | 1991-02-19 | The Procter & Gamble Company | Iron-calcium mineral supplements with enhanced bioavailability |
US4786510A (en) * | 1987-07-02 | 1988-11-22 | The Procter & Gamble Company | Calcium-iron mineral supplements |
DE3801382A1 (en) * | 1988-01-19 | 1989-08-03 | Ebner Anlagen & Apparate | Process and plant for converting sodium sulphate into sodium hydroxide |
ES2060737T3 (en) * | 1988-02-25 | 1994-12-01 | Yamanouchi Europ Bv | PROCEDURE FOR PREPARING A PHARMACEUTICAL GRANULATE. |
HU201880B (en) | 1988-06-21 | 1991-01-28 | Semmelweis Orvostudomanyi Egye | Process for producing pharmaceutical compositions for profilacting and treating renal diseases and for diminishing frequency of extracorporalis dialysis |
GB8826333D0 (en) | 1988-11-10 | 1988-12-14 | Unilever Plc | Oral compositions |
GB8902581D0 (en) | 1989-02-06 | 1989-03-22 | Telephone Cables Ltd | Optical fibre cable core |
US5153156A (en) | 1989-04-18 | 1992-10-06 | Aristech Chemical Corporation | Process for making efficient anionic clay catalyst, catalysts made thereby, and method of making isophorone |
FR2647433B1 (en) * | 1989-05-23 | 1991-10-31 | Lafarge Coppee Da | PROCESS FOR THE AQUEOUS PREPARATION OF PURIFIED CALCIUM SULFATE |
US4970079A (en) | 1989-06-05 | 1990-11-13 | Purdue Research Foundation | Method and composition of oxy-iron compounds for treatment of hyperphosphatemia |
US5112604A (en) | 1989-09-01 | 1992-05-12 | Riker Laboratories, Inc. | Oral suspension formulation |
ES2018952A6 (en) | 1989-10-17 | 1991-05-16 | Walton Sa | Procedure for preparation of antacid compositions with a prolonged gastric residence time. |
JP2918619B2 (en) | 1990-04-06 | 1999-07-12 | 花王株式会社 | Method for producing metal magnetic powder and coating film for magnetic recording medium |
JPH0414849A (en) * | 1990-05-09 | 1992-01-20 | Shibayama Kikai Kk | Method of removing a semiconductor wafer in chuck mechanism |
ATE136869T1 (en) | 1990-06-08 | 1996-05-15 | Commw Scient Ind Res Org | SORPENT FOR ETHYLENE |
US5300302A (en) | 1990-10-04 | 1994-04-05 | Nestec S.A. | Pharmaceutical composition in gel form in a dispensing package |
DE4036757A1 (en) * | 1990-11-17 | 1992-05-21 | Bayer Ag | ANTAZIDA PREPARATION WITH EXTENDED STOMACH TEMPERING |
GB2253164B (en) * | 1991-02-22 | 1994-10-05 | Hoechst Uk Ltd | Improvements in or relating to electrostatic coating of substrates of medicinal products |
US5246899A (en) * | 1991-08-16 | 1993-09-21 | Amoco Corporation | Simplified preparation of hydrotalcite-type clays |
JPH05208816A (en) * | 1992-01-28 | 1993-08-20 | Sumitomo Metal Mining Co Ltd | Production of cerium hydroxide and cerium oxide |
WO1993022237A1 (en) | 1992-04-30 | 1993-11-11 | J.M. Huber Corporation | Method for production of synthetic hydrotalcite |
US5380542A (en) | 1992-06-19 | 1995-01-10 | Rhone-Poulenc Specialties Chemical Co. | Dietary fiber compositions for use in foods |
US5273767A (en) | 1992-09-09 | 1993-12-28 | Merck & Co., Inc. | Rapidly hydrating gums |
WO1994009798A1 (en) | 1992-10-29 | 1994-05-11 | C-P Technology Limited Partnership | Mixtures or complexes containing calcium and sulfate |
NL9201907A (en) * | 1992-11-02 | 1994-06-01 | Tno | Peristaltic mixing reactor and peristaltic valve pump. |
DE4239442C2 (en) * | 1992-11-24 | 2001-09-13 | Sebo Gmbh | Use of an adsorbent material modified with polynuclear metal oxide hydroxides for the selective elimination of inorganic phosphate from protein-containing liquids |
CA2110313C (en) * | 1992-12-01 | 2004-10-26 | Edward John Roche | Pharmaceutical compositions containing a guanidinothiazole compound and antacids |
US5506248A (en) * | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
TW397686B (en) * | 1993-08-11 | 2000-07-11 | Takeda Chemical Industries Ltd | Antacid compositions and pharmaceutical compositions |
WO1995011033A1 (en) | 1993-10-22 | 1995-04-27 | Commonwealth Scientific And Industrial Research Organisation | Polyoxometallates in the treatment of flavivirus infections |
TW390813B (en) | 1994-04-29 | 2000-05-21 | Merck & Co Inc | Wet granulation formulation for bisphosphonic acids |
EP0782438B1 (en) | 1994-09-21 | 2000-08-09 | Unilever N.V. | Oral compositions |
ATE408007T1 (en) | 1995-09-20 | 2008-09-15 | Univ Queensland | NUCLEOTIDE SEQUENCES THAT CODE FOR ACC SYNTHASE ENZYMES FROM PAPAYA |
NZ325747A (en) * | 1996-01-25 | 1999-01-28 | Colin Leslie Young | Stomach-action molluscicides |
SE9602442D0 (en) | 1996-06-20 | 1996-06-20 | Astra Ab | Administration of pharmaceuticals |
AU713462B2 (en) * | 1996-07-12 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Quickly disintegrable compression-molded materials and process for producing the same |
JPH1059842A (en) | 1996-08-13 | 1998-03-03 | Lion Corp | Composition for tablet and making tablet |
JPH10101569A (en) | 1996-10-01 | 1998-04-21 | Eisai Co Ltd | Antacid |
JPH10236960A (en) | 1997-02-24 | 1998-09-08 | Lion Corp | Composition containing antacid agent |
TW592727B (en) | 1997-04-04 | 2004-06-21 | Chugai Pharmaceutical Co Ltd | Phosphate-binding polymer preparations |
JP3835638B2 (en) | 1997-06-13 | 2006-10-18 | カルソニックカンセイ株式会社 | Air conditioner for automobile |
GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
US6028023A (en) * | 1997-10-20 | 2000-02-22 | Bulldog Technologies U.S.A., Inc. | Process for making, and use of, anionic clay materials |
DE69901938T3 (en) | 1998-03-06 | 2012-08-02 | Aptalis Pharma S.R.L. | FAST CRUMPING TABLET |
JPH11335269A (en) * | 1998-05-19 | 1999-12-07 | Hisamitsu Pharmaceut Co Inc | Solid pharmaceutical preparation for oral administration of gene-related medicine |
KR100414849B1 (en) * | 1998-07-10 | 2004-01-13 | 모토로라 인코포레이티드 | Method and apparatus in a wireless communication system for using a selective call receiver to provide demographic information, redeem coupons, and emulate affinity cards |
US6171678B1 (en) * | 1998-07-14 | 2001-01-09 | Bayer Antwerp N.V. | Polyurethane carpet backings with improved tuft bind |
JP2000086537A (en) | 1998-09-11 | 2000-03-28 | Fuji Chem Ind Co Ltd | Inorganic compound saccharide composition, vehicle, rapidly disintegrating compression molded product, and their production |
SA99191255B1 (en) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | celecoxib compounds |
KR100331529B1 (en) * | 1999-06-16 | 2002-04-06 | 민경윤 | Composition for Oral Administration of Hardly Soluble Antifungal Agent and Process for the Preparation Thereof |
US6448323B1 (en) * | 1999-07-09 | 2002-09-10 | Bpsi Holdings, Inc. | Film coatings and film coating compositions based on polyvinyl alcohol |
US6177581B1 (en) * | 1999-10-12 | 2001-01-23 | The Dow Chemical Company | Mixed-metal chelates and process for the preparation thereof |
US6733780B1 (en) * | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
DE19958007A1 (en) | 1999-12-02 | 2001-06-07 | Roehm Gmbh | Injection molding process for (meth) acrylate copolymers with tertiary ammonium groups |
AU1222201A (en) | 2000-01-06 | 2001-07-16 | Marantech Holding, Llc | Multivalent electron active compositions and methods of making and using same |
AUPQ533700A0 (en) * | 2000-01-28 | 2000-02-17 | Commonwealth Scientific And Industrial Research Organisation | Soil treatment method |
FR2809407B1 (en) | 2000-05-26 | 2002-08-30 | Rhodia Chimie Sa | USE OF HYDROTALCITE AS A FILLER IN POLYMER COMPOSITIONS |
US20030185886A1 (en) * | 2000-05-26 | 2003-10-02 | Hanmi Pharm. Co., Ltd. | Process for the preparation of rapidly disintegrating tablet |
US6720005B1 (en) * | 2000-07-07 | 2004-04-13 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Coated, platform-generating tablet |
IN192168B (en) | 2000-11-24 | 2004-03-06 | Council Scient Ind Res | |
CA2342007C (en) * | 2001-03-26 | 2009-10-20 | University Technologies International, Inc. | Determination of oil and water compositions of oil/water emulsions using low field nmr relaxometry |
US6576665B2 (en) * | 2001-04-03 | 2003-06-10 | Braintree Laboratories, Inc. | Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption |
AU2002346065A1 (en) * | 2001-07-05 | 2003-01-21 | Marantech Holding, Llc | Methods of using electron active compounds for managing conditions afflicting mammals |
UA80682C2 (en) | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
ES2296960T3 (en) * | 2001-08-27 | 2008-05-01 | Kyowa Chemical Industry Co., Ltd. | COMPRESSED ANTIACIDE AND LAXANT CONTAINING MAGNESIUM OXIDE. |
AR036354A1 (en) | 2001-08-31 | 2004-09-01 | Takeda Chemical Industries Ltd | SOLID PREPARATION |
US20050202082A1 (en) | 2001-09-28 | 2005-09-15 | Tsuneyuki Hibino | Press-coated molded article undergoing quick disintegration |
GB0204771D0 (en) | 2002-02-28 | 2002-04-17 | Phoqus Ltd | Fast disintegrating tablets |
US7300670B2 (en) | 2002-04-03 | 2007-11-27 | Unilab Pharmatech, Ltd. | Oral suspension formulation |
PT1501484E (en) | 2002-04-29 | 2006-10-31 | Egyt Gyogyszervegyeszeti Gyar | METHOD FOR PREPARING TABLETS OF PHARMACEUTICALLY ACTIVE SUBSTANCES OWNING COMPRESSION PROPERTIES UNFAVORABLE WITH A GRANULACAO LIQUID UNDERSTANDING MICROCRYSTALLINE CELLULOSE. |
US20040161474A1 (en) | 2002-05-24 | 2004-08-19 | Moerck Rudi E. | Rare earth metal compounds methods of making, and methods of using the same |
BR0312077B8 (en) | 2002-06-25 | 2017-10-24 | Rhodia | polysaccharide depolymerization method |
CN1326612C (en) | 2002-08-09 | 2007-07-18 | 阿尔伯麦尔荷兰有限公司 | Fischer-tropsch process using an iron-containing layered material |
JP4348426B2 (en) | 2002-08-29 | 2009-10-21 | 独立行政法人産業技術総合研究所 | Highly selective dephosphorizing agent and method for producing the same |
CA2513469C (en) | 2003-01-28 | 2016-05-17 | The University Of Wyoming Research Corporation D/B/A/ Western Research Institute | Bioagent air filtration systems |
AR045068A1 (en) | 2003-07-23 | 2005-10-12 | Univ Missouri | FORMULATION OF IMMEDIATE RELEASE OF PHARMACEUTICAL COMPOSITIONS |
US7381428B2 (en) * | 2003-08-26 | 2008-06-03 | Shire International Licensing B.V. | Stabilized lanthanum carbonate compositions |
AU2004266050B2 (en) | 2003-08-26 | 2009-06-18 | Takeda Pharmaceutical Company Limited | Pharmaceutical formulation comprising lanthanum compounds |
EP1696889A1 (en) | 2003-08-28 | 2006-09-06 | Ranbaxy Laboratories, Ltd. | Pharmaceutical compositions of benzimidazole and processes for their preparation |
US20050260271A1 (en) * | 2004-05-20 | 2005-11-24 | Eastman Kodak Company | Composition comprising layered host material with intercalated functional-active organic compound |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US20060177415A1 (en) | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
GB0502787D0 (en) | 2005-02-10 | 2005-03-16 | Ineos Silicas Ltd | Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use |
JP4823547B2 (en) | 2005-03-28 | 2011-11-24 | 株式会社ジーシー | Paste-like dental alginate impression material composition |
CA2634969A1 (en) | 2005-12-28 | 2007-07-05 | Takeda Pharmaceutical Company Limited | Controlled release solid preparation |
MY157620A (en) | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
AU2007253083B2 (en) | 2006-05-19 | 2012-07-19 | Norbrook Laboratories Limited | Stable aqueous suspension having palatable taste |
EP2918548A1 (en) | 2006-12-14 | 2015-09-16 | Novartis Tiergesundheit AG | Iron(iii) sugar based phosphate adsorbent |
ES2526171T3 (en) | 2006-12-14 | 2015-01-07 | Novartis Ag | Iron (III) -carbohydrate phosphate adsorbent |
EP1946750A1 (en) | 2007-01-18 | 2008-07-23 | The Jordanian Pharmaceutical Manufacturing Co. | Co-precipitate, method for preparing the same and uses thereof |
WO2008129034A1 (en) | 2007-04-20 | 2008-10-30 | Euro Support Catalyst Group Bv | Hydrotalcite-like layered double hydroxide (ldh) composition and process of making same |
GB0714670D0 (en) | 2007-07-27 | 2007-09-05 | Ineos Healthcare Ltd | Use |
GB0720220D0 (en) | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
GB0913525D0 (en) | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
GB201001779D0 (en) | 2010-02-04 | 2010-03-24 | Ineos Healthcare Ltd | Composition |
-
1997
- 1997-09-19 GB GBGB9720061.2A patent/GB9720061D0/en not_active Ceased
-
1998
- 1998-09-18 DK DK98944055T patent/DK1015002T3/en active
- 1998-09-18 AU AU91733/98A patent/AU9173398A/en not_active Abandoned
- 1998-09-18 NZ NZ503136A patent/NZ503136A/en not_active IP Right Cessation
- 1998-09-18 PL PL98339079A patent/PL194211B1/en not_active IP Right Cessation
- 1998-09-18 CN CN2006100928025A patent/CN1911245B/en not_active Expired - Lifetime
- 1998-09-18 JP JP2000512558A patent/JP4149659B2/en not_active Expired - Lifetime
- 1998-09-18 KR KR1020077001491A patent/KR100997504B1/en not_active IP Right Cessation
- 1998-09-18 PT PT98944055T patent/PT1015002E/en unknown
- 1998-09-18 AT AT98944055T patent/ATE332699T1/en active
- 1998-09-18 DK DK06013811.2T patent/DK1759704T3/en active
- 1998-09-18 CA CA2303820A patent/CA2303820C/en not_active Expired - Lifetime
- 1998-09-18 US US09/508,923 patent/US6926912B1/en not_active Expired - Lifetime
- 1998-09-18 AT AT06013811T patent/ATE489958T1/en active
- 1998-09-18 HU HU0900652A patent/HU230611B1/en active IP Right Revival
- 1998-09-18 DE DE69842028T patent/DE69842028D1/en not_active Expired - Lifetime
- 1998-09-18 EP EP06013811A patent/EP1759704B1/en not_active Expired - Lifetime
- 1998-09-18 ES ES06013811T patent/ES2355925T3/en not_active Expired - Lifetime
- 1998-09-18 KR KR1020007002892A patent/KR100823565B1/en not_active IP Right Cessation
- 1998-09-18 WO PCT/GB1998/002834 patent/WO1999015189A1/en not_active Application Discontinuation
- 1998-09-18 BR BR9812223-1A patent/BR9812223A/en not_active Application Discontinuation
- 1998-09-18 CN CNB988092336A patent/CN1268347C/en not_active Expired - Lifetime
- 1998-09-18 DE DE69835217T patent/DE69835217T2/en not_active Expired - Lifetime
- 1998-09-18 ES ES98944055T patent/ES2268788T3/en not_active Expired - Lifetime
- 1998-09-18 PT PT06013811T patent/PT1759704E/en unknown
- 1998-09-18 HU HU0004527A patent/HU227666B1/en unknown
- 1998-09-18 EP EP98944055A patent/EP1015002B1/en not_active Expired - Lifetime
-
2003
- 2003-07-10 US US10/615,797 patent/US7799351B2/en not_active Expired - Fee Related
-
2006
- 2006-09-28 CY CY20061101402T patent/CY1106174T1/en unknown
-
2007
- 2007-03-23 JP JP2007076097A patent/JP4929426B2/en not_active Expired - Lifetime
- 2007-06-05 HK HK07105937.8A patent/HK1098390A1/en not_active IP Right Cessation
- 2007-11-15 JP JP2007296734A patent/JP2008069173A/en active Pending
-
2010
- 2010-07-01 US US12/828,462 patent/US8568792B2/en not_active Expired - Fee Related
-
2011
- 2011-02-14 CY CY20111100186T patent/CY1111199T1/en unknown
-
2013
- 2013-10-28 US US14/065,162 patent/US9242869B2/en not_active Expired - Fee Related
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU414849A1 (en) * | 1971-05-21 | 1977-09-05 | Харьковский домостроительный комбинат | Concrete mix |
DE3402878A1 (en) * | 1984-01-27 | 1985-08-01 | Algina AG, Zug | MEDICINAL PRODUCTS AND THE USE OF HEAVY-SOLUBLE CALCIUM AND / OR MAGNESIUM COMPOUNDS AS MEDICINAL PRODUCTS |
JPS6136222A (en) * | 1984-07-26 | 1986-02-20 | Chugai Pharmaceut Co Ltd | Remedy for hyperphosphatemia |
JPS62145024A (en) * | 1985-12-19 | 1987-06-29 | Asahi Chem Ind Co Ltd | Immobilizing agent for phosphate ion |
GB2254556A (en) * | 1991-04-11 | 1992-10-14 | Fisons Plc | Linolenic acid formulations |
JPH05155776A (en) * | 1991-12-02 | 1993-06-22 | Otsuka Pharmaceut Factory Inc | Therapeutic agent for hyperphosphatemia |
WO1996030029A1 (en) * | 1995-03-25 | 1996-10-03 | Johnson Matthey Public Limited Company | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
US5571336A (en) * | 1995-09-29 | 1996-11-05 | Wurzburger; Stephen R. | Base solution for cleaning aluminum |
WO1997022266A1 (en) * | 1995-12-19 | 1997-06-26 | Vifor (International) Ag | Adsorbent for phosphate from an aqueous medium, production and use of said adsorbent |
US5654011A (en) * | 1996-07-30 | 1997-08-05 | Energetics, Inc. | Dietary supplements |
Non-Patent Citations (7)
Title |
---|
BUDAVARI ET AL, EDS.: "The Merck Index", 1996, MERCK & CO INC., XP002091238 * |
DATABASE WPI Week 7832, Derwent World Patents Index; AN 78-58210a, XP002091239 * |
DATABASE WPI Week 8731, Derwent World Patents Index; AN 87-218330 * |
DATABASE WPI Week 9329, Derwent World Patents Index; AN 93-232270 * |
PATENT ABSTRACTS OF JAPAN vol. 010, no. 194 (C - 358) 8 July 1986 (1986-07-08) * |
PATENT ABSTRACTS OF JAPAN vol. 011, no. 371 (C - 462) 3 December 1987 (1987-12-03) * |
PATENT ABSTRACTS OF JAPAN vol. 017, no. 551 (C - 1117) 5 October 1993 (1993-10-05) * |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7799351B2 (en) | 1997-09-19 | 2010-09-21 | Ineos Healthcare Limited | Metal compounds, mixed or sulphated, as phosphate binders |
US9242869B2 (en) | 1997-09-19 | 2016-01-26 | Opko Ireland Global Holdings, Ltd. | Metal compounds mixed or sulphated, as phosphate binders |
EP1046410A3 (en) * | 1999-04-20 | 2002-08-14 | Vitasyn GmbH | Calcium and magnesium containing phosphate binding agent for the treatment of hyperphosphatemia |
EP1046410A2 (en) * | 1999-04-20 | 2000-10-25 | Vitasyn GmbH | Calcium and magnesium containing phosphate binding agent for the treatment of hyperphosphatemia |
US7588782B2 (en) | 2002-05-24 | 2009-09-15 | Altairnano, Inc. | Rare earth metal compositions for treating hyperphosphatemia and related methods |
US8715603B2 (en) | 2002-05-24 | 2014-05-06 | Spectrum Pharmaceuticals, Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
US8852543B2 (en) | 2002-05-24 | 2014-10-07 | Spectrum Pharmaceuticals, Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
US9511091B2 (en) | 2002-05-24 | 2016-12-06 | Spectrum Pharmaceuticals, Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
EP1647524A3 (en) * | 2002-08-14 | 2006-09-13 | Altair Nanomaterials Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
EP1647524A2 (en) * | 2002-08-14 | 2006-04-19 | Altair Nanomaterials Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
WO2004016553A3 (en) * | 2002-08-14 | 2004-07-29 | Altair Nanomaterials Inc | Rare earth metal compounds, methods of making, and methods of using the same |
EA009766B1 (en) * | 2002-08-14 | 2008-04-28 | Элтэйрнано Инк. | Rare earth metal compounds, methods of making and methods of using the same |
WO2004016553A2 (en) * | 2002-08-14 | 2004-02-26 | Altair Nanomaterials Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
EA012877B1 (en) * | 2002-08-14 | 2009-12-30 | Элтэйрнано Инк. | Rare earth metal compounds, methods of making, and methods of using the same |
US7465465B2 (en) * | 2003-08-26 | 2008-12-16 | Shire Biochem Inc. | Pharmaceutical formulation comprising lanthanum compounds |
WO2006000547A3 (en) * | 2004-06-28 | 2006-06-22 | Vifor Int Ag | Method for producing an iron sulfate-based phosphate adsorbent |
WO2006000547A2 (en) * | 2004-06-28 | 2006-01-05 | Vifor (International) Ag | Method for producing an iron sulfate-based phosphate adsorbent |
EP1708723A4 (en) * | 2004-07-27 | 2006-12-20 | Shire Pharmaceuticals Inc | Method of treating hyperphosphataemia using lanthanum hydroxycarbonate |
EP3120855A1 (en) | 2005-02-10 | 2017-01-25 | OPKO Ireland Global Holdings, Limited | Pharmaceutically active phosphate binders, their manufacture, compositions containing them and their use |
AU2006213922B2 (en) * | 2005-02-10 | 2011-09-29 | Cytochroma Development Inc. | Pharmaceutically active phosphate binders, their manufacture, compositions containing them and their use |
NO341846B1 (en) * | 2005-02-10 | 2018-02-05 | Cytochroma Dev Inc | Substance for use as a medicament, process for its preparation, pharmaceutical formulation and process for preparation thereof. |
WO2006085079A2 (en) * | 2005-02-10 | 2006-08-17 | Ineos Healthcare Limited | Pharmaceutically active phosphate binders, their manufacture, compositions containing them and their use |
US20080206358A1 (en) * | 2005-02-10 | 2008-08-28 | Ineos Healthcare Limited | Pharmaceutically Active Compounds, their Manufacture, Compositions Containing them, and their Use |
WO2006085079A3 (en) * | 2005-02-10 | 2006-12-14 | Ineos Silicas Ltd | Pharmaceutically active phosphate binders, their manufacture, compositions containing them and their use |
TWI461201B (en) * | 2005-02-10 | 2014-11-21 | Cytochroma Dev Inc | Pharmaceutically active compounds, their manufacture, compositions containing them and their use |
NO20171769A1 (en) * | 2005-02-10 | 2007-11-12 | Cytochroma Dev Inc | Process for the preparation of a substance for use as a medicament |
US20120093943A1 (en) * | 2005-02-10 | 2012-04-19 | Maurice Sydney Newton | Pharmaceutically active compounds, their manufacture, compositions containing them, and their use |
KR101794747B1 (en) | 2006-01-31 | 2017-11-07 | 사이토크로마 디벨럽먼트 인크. | Granular material comprising water-insoluble inorganic phosphate binders |
US9168270B2 (en) | 2006-01-31 | 2015-10-27 | Opko Ireland Global Holdings, Ltd. | Water-insoluble, iron-containing mixed metal, granular material |
NO345039B1 (en) * | 2006-01-31 | 2020-08-31 | Cytochroma Dev Inc | Granular material and unit dose |
AU2007211375B2 (en) * | 2006-01-31 | 2013-08-29 | Cytochroma Development Inc. | Granular material comprising water- insoluble inorganic phosphate binders |
CN103751114A (en) * | 2006-01-31 | 2014-04-30 | 塞托克罗马发展公司 | Granular material containing water-insoluble inorganic phosphate binders |
WO2007088343A3 (en) * | 2006-01-31 | 2008-01-24 | Ineos Healthcare Ltd | Granular material comprising water- insoluble inorganic phosphate binders |
AU2016213745B2 (en) * | 2006-01-31 | 2019-03-14 | Cytochroma Development Inc. | Granular Material Comprising Water-Insoluble Inorganic Phosphate Binders |
NO342570B1 (en) * | 2006-01-31 | 2018-06-18 | Cytochroma Dev Inc | Granular material, process for its preparation, and unit dose for oral administration. |
US9907816B2 (en) | 2006-01-31 | 2018-03-06 | Opko Ireland Global Holdings, Ltd. | Water-insoluble, iron-containing mixed metal, granular material |
CN101378730A (en) * | 2006-01-31 | 2009-03-04 | 英力士保健有限公司 | Granular material comprising water-insoluble inorganic phosphate binders |
WO2007088343A2 (en) * | 2006-01-31 | 2007-08-09 | Ineos Healthcare Limited | Granular material comprising water- insoluble inorganic phosphate binders |
US8252310B2 (en) | 2006-12-14 | 2012-08-28 | Novartis Ag | Manufacture process |
EP1932807A1 (en) * | 2006-12-14 | 2008-06-18 | Novartis AG | Inorganic compounds |
KR101653691B1 (en) | 2007-07-27 | 2016-09-02 | 사이토크로마 디벨럽먼트 인크. | Mixed metal compounds used as antacids |
US10201501B2 (en) | 2007-07-27 | 2019-02-12 | Opko Ireland Global Holdings, Ltd. | Mixed metal compounds used as antacids |
KR20150034245A (en) * | 2007-07-27 | 2015-04-02 | 사이토크로마 디벨럽먼트 인크. | Mixed metal compounds used as antacids |
EP3210600A1 (en) | 2007-07-27 | 2017-08-30 | Opko Ireland Global Holdings, Ltd. | Mixed metal compounds used as antacids |
WO2009016349A1 (en) * | 2007-07-27 | 2009-02-05 | Ineos Healthcare Limited | Mixed metal compounds used as antacids |
KR101653690B1 (en) | 2007-07-27 | 2016-09-02 | 사이토크로마 디벨럽먼트 인크. | Mixed metal compounds used as antacids |
KR20100035167A (en) * | 2007-07-27 | 2010-04-02 | 이네오스 헬스케어 리미티드 | Mixed metal compounds used as antacids |
WO2009050468A1 (en) | 2007-10-16 | 2009-04-23 | Ineos Healthcare Limited | Mixed metal compounds for treatment of hyperphos phataemia |
US10155040B2 (en) | 2007-10-16 | 2018-12-18 | Opko Ireland Global Holdings, Ltd. | Mixed metal compounds for treatment of hyperphosphataemia |
AU2008313466B2 (en) * | 2007-10-16 | 2014-10-23 | Cytochroma Development Inc. | Mixed metal compounds for treatment of hyperphos phataemia |
US9610267B2 (en) | 2009-04-10 | 2017-04-04 | Cypress Pharmaceuticals, Inc. | Phosphate-binding magnesium salts and uses thereof |
US9339481B2 (en) | 2009-04-10 | 2016-05-17 | Cypress Pharmaceuticals, Inc. | Phosphate-binding magnesium salts and uses thereof |
US9889157B2 (en) | 2009-04-10 | 2018-02-13 | Cypress Pharmaceuticals, Inc. | Phosphate-binding magnesium salts and uses thereof |
US9066917B2 (en) | 2009-08-03 | 2015-06-30 | Cytochroma Development Inc. | Mixed metal compound |
US9314481B2 (en) | 2009-08-03 | 2016-04-19 | Opko Ireland Global Holdings, Ltd. | Method |
WO2011015859A1 (en) | 2009-08-03 | 2011-02-10 | Ineos Healthcare Limited | Method |
EP3611131A1 (en) | 2009-08-03 | 2020-02-19 | Opko Ireland Global Holdings, Ltd. | Magnesium-iron layered double hydroxides, their manufacture and their use for treatment of hyperphosphataemia |
WO2011048097A1 (en) * | 2009-10-21 | 2011-04-28 | Freie Universität Berlin | Bismuth-containing composition for reducing the phosphate concentration in fluids |
US9566302B2 (en) | 2010-02-04 | 2017-02-14 | Opko Ireland Global Holdings, Ltd. | Composition comprising mixed metal compounds and xanthan gum |
WO2011095812A2 (en) | 2010-02-04 | 2011-08-11 | Ineos Healthcare Limited | Composition |
US8961917B2 (en) | 2010-05-12 | 2015-02-24 | Spectrum Pharmaceuticals, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
US10350240B2 (en) | 2010-05-12 | 2019-07-16 | Spectrum Pharmaceuticals, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
US11406663B2 (en) | 2010-05-12 | 2022-08-09 | Unicycive Therapeutics, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
US10150784B2 (en) | 2012-11-30 | 2018-12-11 | Cypress Pharmaceuticals, Inc. | Crystal polymorph of magnesium glycinate dihydrate and process for its preparation |
US9394318B2 (en) | 2012-11-30 | 2016-07-19 | Cypress Pharmaceuticals, Inc. | Crystal polymorph of magnesium glycinate dihydrate and process for its preparation |
WO2020084349A1 (en) | 2018-10-25 | 2020-04-30 | Opko Ireland Global Holdings, Ltd | Methods of treatment with mixed metal compounds |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8568792B2 (en) | Metal compounds, mixed or sulphated, as phosphate binders | |
AU702073B2 (en) | Pharmaceutical composition containing selected lanthanum carbonate hydrates | |
ES2751325T3 (en) | Double hydroxides with magnesium-iron layers, their production and use for the treatment of hyperphosphatemia | |
KR101552183B1 (en) | Mixed metal compounds for treatment of hyperphos phataemia | |
EP2125847B1 (en) | Ligand modified poly oxo-hydroxy metal ion materials, their uses and processes for their preparation | |
KR101491531B1 (en) | Pharmaceutically active phosphate binders, their manufacture, compositions containing them and their use | |
Ekosse et al. | Geophagic clays: Their mineralogy, chemistry and possible human health effects | |
MXPA00002379A (en) | Metal compounds, mixed or sulphated, as phosphate binders | |
Rankin et al. | The evaluation of novel mixed metal hydroxy‐carbonates as phosphate binders: an in‐vivo study in the rat | |
WO2018229789A1 (en) | An inorganic base antacid compound with improved and novel properties | |
WO2006132321A1 (en) | Agent for preventing, ameliorating and treating phosphorus-induced disorder, oral preparation for adsorbing phosphate ion in food, drink or drug and method of producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98809233.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 503136 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/002379 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2303820 Country of ref document: CA Ref document number: 2303820 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007002892 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998944055 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09508923 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998944055 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007002892 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998944055 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007002892 Country of ref document: KR |